4+ day, 3+ hour ago   (280+ words) Connected datasets provide a 360° view of the patient NEW YORK, Sept. 10, 2026 (GLOBE NEWSWIRE) -- Citeline, a Norstella company and leading provider of clinical, drug and commercial intelligence for the life sciences industry, introduces Patient Intelligence, providing a complete view of the…...

6+ day, 11+ hour ago   (77+ words) Novartis provides update on delpacibart etedesiran (del-desiran) Phase III HARBOR study for the treatment of myotonic dystrophy type 1 (DM1) LEADING EDGE MATERIALS DRILLS NEAR-MINE TO TEST FOR A LARGER REGIONAL GRAPHITE SYSTEM AT WOXNA, SWEDEN PRESS RELEASE: CMB.TECH announces special…...

1+ week, 6+ hour ago   (184+ words) The overall safety and tolerability of semaglutide observed in STEP Young were consistent with previous Novo Nordisk paediatric and adult trials with semaglutide and liraglutide, and no new safety concerns were identified. Furthermore, no safety concerns were identified for growth…...

1+ week, 6+ day ago   (436+ words) Medicel AG expands its SOFT TIP I/A portfolio with the launch of BICEL™ SOFT TIP I/A terralution™ – bimanual sustainable I/A (irrigation / aspiration) for gentle tissue interaction – at the ESCRS Congress 2026 in London. ALTENRHEIN, Switzerland, Sept. 01, 2026 (GLOBE NEWSWIRE)…...

2+ week, 8+ hour ago   (183+ words) XYRA Announces First Patient Dosed in Europe in the Phase 2/3 HARBOR-AF Study of Budiodarone in Paroxysmal and Persistent Atrial Fibrillation LOS ALTOS, California, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Open-label, dose-escalation study using cardiac rhythm data from implantable and wearable AF monitors allows…...